Dr. Reddy’s Announces May Exit of Global Head of IPDO Sushrut Kulkarni
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dr Reddy’s Laboratories ( (RDY) ) has shared an announcement.
Dr. Reddy’s Laboratories has disclosed a senior management change, announcing that Sushrut Kulkarni will step down as Global Head of IPDO and as a member of the senior management team. The move was formally communicated to stock exchanges on February 9, 2026, in compliance with Indian listing regulations, underscoring the company’s adherence to governance and disclosure norms.
Kulkarni has resigned to pursue opportunities outside the company and will cease employment at the close of business on May 8, 2026, while supporting a smooth transition during his notice period. The leadership change in the IPDO function, which is central to product development, may have strategic implications for pipeline execution and could be closely watched by investors tracking Dr. Reddy’s innovation and growth plans.
The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based global pharmaceutical company headquartered in Hyderabad, Telangana. It develops and manufactures generic medicines and other pharmaceutical products for markets including India and international exchanges where its shares are listed, such as the New York Stock Exchange and major Indian bourses.
Average Trading Volume: 1,432,413
Technical Sentiment Signal: Buy
Current Market Cap: $11.41B
For a thorough assessment of RDY stock, go to TipRanks’ Stock Analysis page.
